Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial.

ABSTRACT: During the latest pandemic, the RECOVERY study showed the benefits of dexamethasone (DEX) use in COVID-19 patients. Obesity has been proven to be an independent risk factor for severe forms of infection, but little information is available in the literature regarding DEX dose adjustment according to body weight. We conducted a prospective, observational, exploratory study at Geneva University Hospitals to assess the impact of weight on DEX pharmacokinetics (PK) in normal-weight versus obese COVID-19 hospitalized patients. Two groups of patients were enrolled: normal-weight and obese (body mass index [BMI] 18.5-25 and >30 kg/m² , respectively). All patients received the standard of care therapy of 6 mg DEX orally. Blood samples were collected, and DEX concentrations were measured

SUBMITTER: Abouir K 

PROVIDER: S-EPMC9283739 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature